BRPI0508084A - método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo - Google Patents

método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo

Info

Publication number
BRPI0508084A
BRPI0508084A BRPI0508084-3A BRPI0508084A BRPI0508084A BR PI0508084 A BRPI0508084 A BR PI0508084A BR PI0508084 A BRPI0508084 A BR PI0508084A BR PI0508084 A BRPI0508084 A BR PI0508084A
Authority
BR
Brazil
Prior art keywords
treatment
meridamycin
salt
neurological disorder
disorder
Prior art date
Application number
BRPI0508084-3A
Other languages
English (en)
Inventor
Edmund Idris Graziani
Kevin Pong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0508084A publication Critical patent/BRPI0508084A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"MéTODO PARA O TRATAMENTO DE UM DISTúRBIO NEUROLóGICO, E, USO DE MERIDAMICINA OU UM SAL DO MESMO" A invenção refere-se, em parte, ao uso de ligandos imunofilina não-imunossupressores, tais que meridamicina,no tratamento de distúrbios neurológicos.
BRPI0508084-3A 2004-03-02 2005-02-25 método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo BRPI0508084A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54943004P 2004-03-02 2004-03-02
PCT/US2005/006246 WO2005084673A1 (en) 2004-03-02 2005-02-25 Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents

Publications (1)

Publication Number Publication Date
BRPI0508084A true BRPI0508084A (pt) 2007-07-17

Family

ID=34919492

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508084-3A BRPI0508084A (pt) 2004-03-02 2005-02-25 método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo

Country Status (8)

Country Link
US (1) US20050197356A1 (pt)
EP (1) EP1720548A1 (pt)
JP (1) JP2007526312A (pt)
CN (1) CN1929837A (pt)
AU (1) AU2005219389A1 (pt)
BR (1) BRPI0508084A (pt)
CA (1) CA2556771A1 (pt)
WO (1) WO2005084673A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1720886A1 (en) * 2004-03-02 2006-11-15 Wyeth Macrolides and methods for producing same
US7507752B2 (en) * 2004-06-03 2009-03-24 Wyeth Biosynthetic gene cluster for the production of a complex polyketide
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
KR20080099317A (ko) * 2006-03-07 2008-11-12 와이어쓰 신경퇴행성 질환 치료를 위한 메리다마이신 유사체
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
AR063984A1 (es) * 2006-11-28 2009-03-04 Wyeth Corp Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
CA2676613A1 (en) * 2007-01-29 2008-08-07 Wyeth Immunophilin ligands and methods for modulating immunophilin and calcium channel activity
WO2011045166A1 (en) 2009-09-24 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) * 1993-02-02 1993-03-17 Sandoz Ltd Compounds
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US7041283B1 (en) * 2001-02-16 2006-05-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods of using immunophilin binding drugs to improve integration and survival of neuronal cell transplants

Also Published As

Publication number Publication date
EP1720548A1 (en) 2006-11-15
CN1929837A (zh) 2007-03-14
US20050197356A1 (en) 2005-09-08
CA2556771A1 (en) 2005-09-15
JP2007526312A (ja) 2007-09-13
WO2005084673A1 (en) 2005-09-15
AU2005219389A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
BRPI0812889A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal.
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
SG155912A1 (en) B-cell reduction using cd37-specific and cd20-specific binding molecules
WO2003096983A3 (en) Method of treating dyslipidemic disorders
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
SG170813A1 (en) New compounds
BR0116792A (pt) Derivados de diamina de triazol substituìdos como inibidores de quinase
NZ608860A (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration
WO2005037203A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
CL2007003155A1 (es) Compuestos derivados de 3,7-diazabiciclo[3.3.0]octano o 3,7-diazabiciclo[3.3.1]nonano, moduladores de receptores nicotinicos neuronales; composicion farmaceutica; y uso en el tratamiento de trastornos del snc.
WO2007089715A3 (en) Method for treatment of neuropathic pain
WO2008069889A3 (en) Methods of treating hemolytic anemia
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
GB0327380D0 (en) Method
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
WO2005019270A3 (en) Endotheliase-2 ligands
MX351062B (es) Proteinas de fusion para el tratamiento del snc.
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
SG166768A1 (en) Agonist anti-trkc antibodies and methods using same
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
GB0305153D0 (en) Identification of therapeutic compounds
WO2006042137A3 (en) Methods for identifying parkinson's disease therapeutics

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.